Form 4: TNF Pharmaceuticals Executive Receives Stock Grant
Insider Transaction (Form 4)
Joshua Silverman, Executive Chairman and a Director of TNF Pharmaceuticals, Inc., reported multiple transactions in common stock on July 10, 2026.
Summary
- Grant/award: acquired 16,620 Common Stock on July 10, 2026; holds 133,455 after (Direct).
- Grant/award: acquired 77,390 Common Stock on October 1, 2026; holds 210,845 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Joshua Silverman — Director, Officer (Executive Chairman)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-10 | Grant/award | Common Stock | 16,620 | — | — | 133,455 |
| 2026-10-01 | Grant/award | Common Stock | 77,390 | — | — | 210,845 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-10 | Grant/award (16,620 shares) |
| 2026-10-01 | Grant/award (77,390 shares) |
Keywords
insider transaction, Form 4, QCLS, Q/C TECHNOLOGIES, INC., neutral, Joshua Silverman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.